Cancer treatment reviews最新文献

{"title":"Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer","authors":"Elisa D'Agostino ,&nbsp;Luciana Mastrodomenico ,&nbsp;Ornella Ponzoni ,&nbsp;Cinzia Baldessari ,&nbsp;Claudia Piombino ,&nbsp;Stefania Pipitone ,&nbsp;Maria Giuseppa Vitale ,&nbsp;Roberto Sabbatini ,&nbsp;Massimo Dominici ,&nbsp;Angela Toss","doi":"10.1016/j.ctrv.2024.102723","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102723","url":null,"abstract":"<div><p>Endometrial cancer (EC) incidence and mortality rates have been increasing, particularly among young females. Although more than 90% of ECs are sporadic, 5–10% are hereditary, a majority of which occurs within Hereditary Non-Polyposis Colorectal Cancer syndrome (HNPCC) or Lynch syndrome. The traditional histopathological classification differentiates EC between two main groups: type I (or endometrioid) and type II (including all other histopathological subtypes). However, this classification lacks reproducibility and does not account for the emerging molecular heterogeneity. In 2013, The Cancer Genome Atlas (TCGA) project proposed EC molecular classification defining four groups with different prognostic and predictive values and the current international guidelines are progressively establishing EC risk stratification and treatment based on both histopathological and molecular criteria. Our manuscript aims to summarize the current state of EC molecular characterizations, including germline alterations at the basis of hereditary EC predisposition, to discuss their clinical utility as prognostic and predictive markers.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":null,"pages":null},"PeriodicalIF":11.8,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140328231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"If it’s a target, it’s a pan-cancer target: Tissue is not the issue","authors":"Jacob J. Adashek ,&nbsp;Shumei Kato ,&nbsp;Jason K. Sicklick ,&nbsp;Scott M. Lippman ,&nbsp;Razelle Kurzrock","doi":"10.1016/j.ctrv.2024.102721","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102721","url":null,"abstract":"<div><p>Cancer is traditionally diagnosed and treated on the basis of its organ of origin (e.g., lung or colon cancer). However, organ-of-origin diagnostics does not reveal the underlying oncogenic drivers. Fortunately, molecular diagnostics have advanced at a breathtaking pace, and it is increasingly apparent that cancer is a disease of the genome. Hence, we now have multiple genomic biomarker-based, tissue-agnostic Food and Drug Administration approvals for both gene- and immune-targeted therapies (larotrectinib/entrectinib, for <em>NTRK</em> fusions; selpercatinib, <em>RET</em> fusions; dabrafenib plus trametinib, <em>BRAF^V600E</em> mutations; pembrolizumab/dostarlimab, microsatellite instability; and pembrolizumab for high tumor mutational burden; pemigatinib is also approved for <em>FGFR1</em>-rearranged myeloid/lymphoid neoplasms). There are emerging targets as well, including but not limited to <em>ALK</em>, <em>BRCA</em> and/or homologous repair deficiency, <em>ERBB2 (HER2), IDH1/2, KIT, KRAS^G12C, NRG1,</em> and <em>VHL.</em> Many tissue-agnostic approvals center on rare/ultra-rare biomarkers (often &lt; 1 % of cancers), necessitating screening hundreds of tumors to find a single one harboring the cognate molecular alteration. Approval has generally been based on small single-arm studies (&lt;30–100 patients) with high response rates (&gt;30 % to &gt; 75 %) of remarkable durability. Because of biomarker rarity, single-gene testing is not practical; next generation sequencing of hundreds of genes must be performed to obtain timely answers. Resistance to biomarker-driven therapeutics is often due to secondary mutations or co-driver gene defects; studies are now addressing the need for customized drug combinations matched to the complex molecular alteration portfolio in each tumor. Future investigation should expand tissue-agnostic therapeutics to encompass both hematologic and solid malignancies and include biomarkers beyond those that are DNA-based.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":null,"pages":null},"PeriodicalIF":11.8,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224000483/pdfft?md5=3f4ec6cafd3249179b5fbfb12b2ffac3&pid=1-s2.0-S0305737224000483-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672]","authors":"Arianna Dri ,&nbsp;Grazia Arpino ,&nbsp;Giampaolo Bianchini ,&nbsp;Giuseppe Curigliano ,&nbsp;Romano Danesi ,&nbsp;Michelino De Laurentiis ,&nbsp;Lucia Del Mastro ,&nbsp;Alessandra Fabi ,&nbsp;Daniele Generali ,&nbsp;Alessandra Gennari ,&nbsp;Valentina Guarneri ,&nbsp;Daniele Santini ,&nbsp;Edda Simoncini ,&nbsp;Claudio Zamagni ,&nbsp;Fabio Puglisi","doi":"10.1016/j.ctrv.2024.102714","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102714","url":null,"abstract":"","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":null,"pages":null},"PeriodicalIF":11.8,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224000410/pdfft?md5=54b30bc89ac116a3f3d2bd520ae33f8d&pid=1-s2.0-S0305737224000410-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140138968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers","authors":"Angelika M. Starzer ,&nbsp;Ladislaia Wolff ,&nbsp;Petar Popov ,&nbsp;Barbara Kiesewetter ,&nbsp;Matthias Preusser ,&nbsp;Anna S. Berghoff","doi":"10.1016/j.ctrv.2024.102718","DOIUrl":"10.1016/j.ctrv.2024.102718","url":null,"abstract":"<div><p>Immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) have gained therapeutical significance in cancer therapy over the last years. Due to the high efficacy of each substance group, additive or complementary effects are considered, and combinations are the subject of multiple prospective trials in different tumor entities. The majority of available data results from clinical phase I and II trials. Although regarded as well-tolerated therapies ICI-TKI combinations have higher toxicities compared to monotherapies of one of the substance classes and some combinations were shown to be excessively toxic leading to discontinuation of trials. So far, ICI-TKI combinations with nivolumab + cabozantinib, pembrolizumab + axitinib, avelumab + axitinib, pembrolizumab + lenvatinib have been approved in advanced renal cell (RCC), with pembrolizumab + lenvatinib in endometrial carcinoma and with camrelizumab + rivoceranib in hepatocellular carcinoma (HCC). Several ICI-TKI combinations are currently investigated in phase I to III trials in various other cancer entities. Further, the optimal sequence of ICI-TKI combinations is an important subject of investigation, as cross-resistances between the substance classes were observed. This review reports on clinical trials with ICI-TKI combinations in different cancer entities, their efficacy and toxicity.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":null,"pages":null},"PeriodicalIF":11.8,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224000458/pdfft?md5=dc176d81613cd91a6914c1da75714dfd&pid=1-s2.0-S0305737224000458-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140182271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging gaps in cancer cachexia Care: Current insights and future perspectives","authors":"Carlotta Bianchini ,&nbsp;Pierluigi Bonomo ,&nbsp;Paolo Bossi ,&nbsp;Riccardo Caccialanza ,&nbsp;Alessandra Fabi","doi":"10.1016/j.ctrv.2024.102717","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102717","url":null,"abstract":"<div><p>Cachexia is characterized by severe weight loss and skeletal muscle depletion, and is a threat to cancer patients by worsening their prognosis. International guidelines set indications for the screening and diagnosis of cancer cachexia and suggest interventions (nutritional support, physical exercise, and pharmacological treatments). Nevertheless, real-life experience not always aligns with such indications. We aimed to review the current state of the field and the main advancements, with a focus on real-life clinical practice from the perspectives of oncologists, nutrition professionals, and radiologists. Pragmatic solutions are proposed to improve the current management of the disease, emphasizing the importance of increasing awareness of clinical nutrition’s benefits, fostering multidisciplinary collaboration, promoting early identification of at-risk patients, and leveraging available resources. Given the distinct needs of patients who are receiving oncologic anti-cancer treatments and those in the follow-up phase, the use of tailored approaches is encouraged. The pivotal role of healthcare professionals in managing patients in active treatment is highlighted, while patient and caregiver empowerment should be strengthened in the follow-up phase. Telemedicine and web-based applications represent valuable tools for continuous monitoring of patients, facilitating timely and personalized intervention through effective communication between patients and healthcare providers. These actions can potentially improve the outcomes, well-being, and survival of cancer patients with cachexia.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":null,"pages":null},"PeriodicalIF":11.8,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224000446/pdfft?md5=fedc344b1171acad1c3fd0aac4e9a70a&pid=1-s2.0-S0305737224000446-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140179730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection","authors":"Elena Brozos-Vázquez ,&nbsp;Marta Toledano-Fonseca ,&nbsp;Nicolás Costa-Fraga ,&nbsp;María Victoria García-Ortiz ,&nbsp;Ángel Díaz-Lagares ,&nbsp;Antonio Rodríguez-Ariza ,&nbsp;Enrique Aranda ,&nbsp;Rafael López-López","doi":"10.1016/j.ctrv.2024.102719","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102719","url":null,"abstract":"<div><p>Pancreatic cancer is one of the tumors with the worst prognosis, and unlike other cancers, few advances have been made in recent years. The only curative option is surgery, but only 15–20% of patients are candidates, with a high risk of relapse. In advanced pancreatic cancer there are few first-line treatment options and no validated biomarkers for better treatment selection. The development of targeted therapies in pancreatic cancer is increasingly feasible due to tumor-agnostic treatments, such as PARP inhibitors in patients with <em>BRCA1</em>, <em>BRCA2</em> or <em>PALB2</em> alterations or immunotherapies in patients with high microsatellite instability/tumor mutational burden. In addition, other therapeutic molecules have been developed for patients with <em>KRAS</em> G12C mutation or fusions in <em>NTRK</em> or <em>NRG1</em>. Consequently, there has been a growing interest in biomarkers that may help guide targeted therapy in pancreatic cancer. Therefore, this review aims to offer an updated perspective on biomarkers with therapeutic potential in pancreatic cancer.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":null,"pages":null},"PeriodicalIF":11.8,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S030573722400046X/pdfft?md5=96ec3537f15005b18419db44251fc740&pid=1-s2.0-S030573722400046X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140122558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms","authors":"A. Kyriazoglou ,&nbsp;A. Pagkali ,&nbsp;I. Kotsantis ,&nbsp;P. Economopoulou ,&nbsp;M. Kyrkasiadou ,&nbsp;M. Moutafi ,&nbsp;N. Gavrielatou ,&nbsp;M. Anastasiou ,&nbsp;A. Boulouta ,&nbsp;A. Pantazopoulos ,&nbsp;M. Giannakakou ,&nbsp;A. Digklia ,&nbsp;A. Psyrri","doi":"10.1016/j.ctrv.2024.102716","DOIUrl":"10.1016/j.ctrv.2024.102716","url":null,"abstract":"<div><p>Well-differentiated liposarcomas (WDLPS) and dedifferentiated liposarcomas (DDLPS) account for 60 % of all liposarcomas, reflecting the heterogeneity of this type of sarcoma. Genetically, both types of liposarcomas are characterized by the amplification of <em>MDM2</em> and <em>CDK4</em> genes, which indicates an important molecular event with diagnostic and therapeutic relevance. In both localized WDLPS and DDLPS of the retroperitoneum and the extremities, between 25 % and 30 % of patients have local or distant recurrence, even when perioperatively treated, with clear margins present. The systemic treatment of WDLPS and DDLPS remains a challenge, with anthracyclines as the gold standard for first-line treatment. Several regimens have been tested with modest results regarding their efficacy. Herein we discuss the systemic treatment options for WDLPS and DDLPS and review their reported clinical efficacy results.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":null,"pages":null},"PeriodicalIF":11.8,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140124695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","authors":"Rebecca S. Heist ,&nbsp;Jacob Sands ,&nbsp;Aditya Bardia ,&nbsp;Toshio Shimizu ,&nbsp;Aaron Lisberg ,&nbsp;Ian Krop ,&nbsp;Noboru Yamamoto ,&nbsp;Takahiro Kogawa ,&nbsp;Saba Al-Hashimi ,&nbsp;Simon S.M. Fung ,&nbsp;Anat Galor ,&nbsp;Francesca Pisetzky ,&nbsp;Priyanka Basak ,&nbsp;Cindy Lau ,&nbsp;Funda Meric-Bernstam","doi":"10.1016/j.ctrv.2024.102720","DOIUrl":"10.1016/j.ctrv.2024.102720","url":null,"abstract":"<div><p>Antibody drug conjugates (ADCs) are an emerging class of treatments designed to improve efficacy and decrease toxicity compared with other systemic therapies through the selective delivery of cytotoxic agents to tumor cells. Datopotamab deruxtecan (Dato-DXd) is a novel ADC comprising a topoisomerase I inhibitor payload and a monoclonal antibody directed to trophoblast cell-surface antigen 2 (TROP2), a protein that is broadly expressed in several types of solid tumors. Dato-DXd is being investigated across multiple solid tumor indications. In the ongoing, first-in-human TROPION-PanTumor01 phase I study (ClinicalTrials.gov: NCT03401385), encouraging and durable antitumor activity and a manageable safety profile was demonstrated in patients with advanced/metastatic hormone receptor-positive/human epidermal growth factor receptor<!--> <!-->2-negative breast cancer (HR+/HER2– BC), triple-negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC).</p><p>Improved understanding of the adverse events (AEs) that are associated with Dato-DXd and their optimal management is essential to ensure safe and successful administration. Interstitial lung disease/pneumonitis, infusion-related reactions, oral mucositis/stomatitis, and ocular surface events have been identified as AEs of special interest (AESIs) for which appropriate prevention, monitoring, and management is essential. This article summarizes the incidence of AESIs among patients with HR+/HER2− BC, TNBC, and NSCLC reported in TROPION-PanTumor01. We report our recommendations for AESI prophylaxis, early detection, and management, using experience gained from treating AESIs that occur with Dato-DXd in clinical trials.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":null,"pages":null},"PeriodicalIF":11.8,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224000471/pdfft?md5=42e58372bfd4d21d42fccffff25e1a90&pid=1-s2.0-S0305737224000471-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140124591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to manage waldenström’s macroglobulinemia in 2024","authors":"Alexander Grunenberg ,&nbsp;Christian Buske","doi":"10.1016/j.ctrv.2024.102715","DOIUrl":"10.1016/j.ctrv.2024.102715","url":null,"abstract":"<div><p>Clinical management of Waldenström’s Macroglobulinemia has seen major progress in the recent years, triggered by our improved understanding of the biology of the disease and the development of new therapies. Based on this there are multiple treatment options available for patients with WM ranging from classical immunochemotherapy to targeted approaches blocking key enzymes involved in lymphoma growth. This review summarizes our current knowledge about diagnostics and treatment of this rare but recurrent lymphoma subtype, which often presents a major clinical challenge in daily clinical life.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":null,"pages":null},"PeriodicalIF":11.8,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140055896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design","authors":"Elena Fountzilas ,&nbsp;Apostolia-Maria Tsimberidou ,&nbsp;Henry Hiep Vo ,&nbsp;Razelle Kurzrock","doi":"10.1016/j.ctrv.2024.102703","DOIUrl":"10.1016/j.ctrv.2024.102703","url":null,"abstract":"<div><p>Choosing the right drug(s) for the right patient via advanced genomic sequencing and multi-omic interrogation is the <em>sine qua non</em> of precision cancer medicine. Traditional cancer clinical trial designs follow well-defined protocols to evaluate the efficacy of new therapies in patient groups, usually identified by their histology/tissue of origin of their malignancy. In contrast, precision medicine seeks to optimize benefit in individual patients, i.e., to define who benefits rather than determine whether the overall group benefits. Since cancer is a disease driven by molecular alterations, innovative trial designs, including biomarker-defined tumor-agnostic basket trials, are driving ground-breaking regulatory approvals and deployment of gene- and immune-targeted drugs. Molecular interrogation further reveals the disruptive reality that advanced cancers are extraordinarily complex and individually distinct. Therefore, optimized treatment often requires drug combinations and N-of-1 customization, addressed by a new generation of N-of-1 trials. Real-world data and structured master registry trials are also providing massive datasets that are further fueling a transformation in oncology. Finally, machine learning is facilitating rapid discovery, and it is plausible that high-throughput computing, <em>in silico</em> modeling, and 3-dimensional printing may be exploitable in the near future to discover and design customized drugs in real time.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":null,"pages":null},"PeriodicalIF":11.8,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140055973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}